Skip to main content
Figure 1 | Molecular Cancer

Figure 1

From: Melanoma-associated Chondroitin Sulfate Proteoglycan (MCSP)-targeted delivery of soluble TRAIL potently inhibits melanoma outgrowth in vitro and in vivo

Figure 1

MCSP-restricted induction of apoptosis by anti-MCSP:TRAIL. A M14 and M14.MCSP cells were treated with increasing concentrations of anti-MCSP:TRAIL for 16 h and apoptosis was assessed by ∆ψ. B MCSP-negative cell line M14 and MCSP-positive cell lines M14.MCSP, SK-MEL-28, A2058 and A375M were treated with 500 ng/ml anti-MCSP:TRAIL for 16 h and apoptosis was assessed by ∆ψ. C A375M, A2058 and SK-MEL-28 cells were treated with equimolar concentrations of anti-MCSP:TRAIL, anti-EpCAM:TRAIL, anti-MCSP mAb or anti-EpCAM:TRAIL+anti-MCSP mAb for 16 h and apoptosis was assessed by ∆ψ. D A2058 cells were treated with 500 ng/mL anti-MCSP:TRAIL in the absence or presence of parental MCSP-blocking mAb 9.2.27, TRAIL-neutralizing mAb 2E5 or pan-caspase inhibitor zVAD-fmk for 16 h and apoptosis was assessed by ∆ψ. E A375M and A375M.FADD-DED cells were treated with anti-MCSP:TRAIL or rhTRAIL for 16 h and apoptosis was assessed by ∆ψ. F A375M cells were incubated with anti-TRAIL-R1 (thin line) or anti-TRAIL-R2 (thick line) mAb and expression of TRAIL-R1 and TRAIL-R2 was analyzed by flow cytometry. Shaded area indicates the fluorescence signal when cells were incubated with fluorescent-labeled secondary antibody alone.

Back to article page